Any grade adverse events more common in the combined rilotumumab group than in the placebo group included haematological adverse events ( neutropenia in 44 [ 54 % ] of 81 patients vs 13 [ 33 % ] of 39 patients ; anaemia in 32 [ 40 % ] vs 11 [ 28 % ] ; and thrombocytopenia in nine [ 11 % ] vs none ) , peripheral oedema ( 22 [ 27 % ] vs three [ 8 % ] ) , and venous thromboembolism ( 16 [ 20 % ] vs five [ 13 % ] ) .